Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Ovarian Cancer
Related studies linked through entity extraction aliases.
Role of Surgery in Advanced Ovarian Cancer
- Status
- COMPLETED
- Phase
- N/A
Feasibility of a New Technology for Isolating Circulating Tumour Cells
- Status
- UNKNOWN
- Phase
- NA
Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Deciphering Mechanisms Underlying Cancer Immunogenicity
- Status
- RECRUITING
- Phase
- NA
CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE1
Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
- Status
- RECRUITING
- Phase
- N/A
Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
- Status
- COMPLETED
- Phase
- PHASE3
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
- Status
- UNKNOWN
- Phase
- PHASE1
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
- Status
- WITHDRAWN
- Phase
- PHASE2
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2)
- Status
- COMPLETED
- Phase
- N/A
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer
- Status
- COMPLETED
- Phase
- N/A
APG-2449 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
DCVAC/OvCa and Standard of Care (SoC) in Relapsed Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2